Longest survival follow-up ever reported for immunotherapy treatment in this setting
CHL is strengthening its play in the fast-growing beauty and personal care sector
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The demand in Africa for COVID-19 vaccines has declined
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Subscribe To Our Newsletter & Stay Updated
